First Bank & Trust Buys 1,738 Shares of Pfizer Inc. $PFE

First Bank & Trust boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 71,216 shares of the biopharmaceutical company’s stock after acquiring an additional 1,738 shares during the quarter. First Bank & Trust’s holdings in Pfizer were worth $1,726,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the 1st quarter valued at $27,000. North Capital Inc. purchased a new stake in Pfizer during the 1st quarter valued at $28,000. Bayforest Capital Ltd bought a new stake in Pfizer in the 1st quarter worth $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Pfizer in the fourth quarter valued at about $30,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on PFE shares. Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Jefferies Financial Group upped their price target on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Bank of America increased their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. HSBC reduced their target price on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Finally, Berenberg Bank dropped their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.12.

Pfizer Price Performance

Shares of NYSE:PFE opened at $23.98 on Tuesday. The business has a fifty day moving average price of $24.76 and a 200-day moving average price of $24.25. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $136.34 billion, a PE ratio of 12.76, a PEG ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the business posted $0.60 EPS. Pfizer’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.